Syntekabio said Thursday that it has signed a strategic alliance agreement with Naver Business Platform (NBP) to cooperate in cloud-based genomic big data analysis.
Under the contract, the two companies plan to unite Syntekabio’s artificial intelligence (AI)-based big data analysis solutions and NBP’s cloud platform. Based on the Personal Genome Map, Syntekabio’s solution contains genome big data analysis on various diseases such as cancer and rare diseases.
NBP’s cloud platform is one of the best technologies in its field. The company has also started a consortium with major Korean hospitals such as Severance Hospital and Samsung Medical Center as a cloud service provider for the P-HIS Development and Construction Project late last year. The project aims to integrate the hospital’s medical information and utilize it for treatment.
“The Fourth Industrial Revolution will make a big difference in the healthcare and bio market,” Syntekabio CEO Tyson Kim said. “The company has decided to collaborate with the NBP to compete with global IT companies such as Amazon and Google, who have already entered the healthcare market.”
NBP also seemed enthusiastic about the cooperative accord.
“AI, cloud and genomic big data are among the keywords of the core technology that will change the future of medicine,” NBP CEO Park Won-ki said. “The collaboration is a very encouraging step for the medical field where there is no cloud-based genetic analysis.”
<© Korea Biomedical Review, All rights reserved.>